Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln

Reuters11-12

Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln

Overview

BeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last year
Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations
SEED secures $30 mln financing, achieves IND clearance for RBM39 program

Outlook

BeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitors
Company highlights SEED's IND clearance for RBM39 degrader program in the US and China
BeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefits

Result Drivers

Research and development (R&D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$1.70 mln

Press Release: ID:nGNX29qBv7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582758003?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582758003","market":"us","top_or_hot":-1,"title":"Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>BeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last year</p></li><li><p>Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations</p></li><li><p>SEED secures $30 mln financing, achieves IND clearance for RBM39 program</p></li></ul><p><span>Outlook</span></p><ul><li><p>BeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitors</p></li><li><p>Company highlights SEED's IND clearance for RBM39 degrader program in the US and China</p></li><li><p>BeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefits</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.70 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX29qBv7</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>BeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last year</p></li><li><p>Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations</p></li><li><p>SEED secures $30 mln financing, achieves IND clearance for RBM39 program</p></li></ul><p><span>Outlook</span></p><ul><li><p>BeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitors</p></li><li><p>Company highlights SEED's IND clearance for RBM39 degrader program in the US and China</p></li><li><p>BeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefits</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development (R&amp;D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.70 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX29qBv7</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BYSI","symbol_name":"万春药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D2:1","article_id":"2582758003","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582758003","pubTimestamp":1762949330,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mlnOverviewBeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last yearPlinabulin shows promising results in NSCLC patients at SITC 2025 pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BYSI":"万春药业","BK4139":"生物科技"},"translate_title":"制药商BeyondSpring第三季度净亏损收窄至170万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BYSI":0.9},"content_text":"Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mlnOverviewBeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last yearPlinabulin shows promising results in NSCLC patients at SITC 2025 presentationsSEED secures $30 mln financing, achieves IND clearance for RBM39 programOutlookBeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitorsCompany highlights SEED's IND clearance for RBM39 degrader program in the US and ChinaBeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefitsResult DriversResearch and development (R&D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$1.70 mlnPress Release: ID:nGNX29qBv7For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582758003","isCrawlerRequest":true}